i never even knew 450 had efficacy in GT3 (or GT 2 for that matter) until they started trials there's no preclinical data that would suggest coverage beyond GT1 that i could find anywhere seems to make perfect sense to have 2 shots on goal for a difficult (by DAA standards) to treat subtype like GT3. PIs have had a history of toxicity so why not get them both in the clinic..
Market Data 
Markets 
AI
